Table 1.
Patient characteristics (N = 227 patients with adequate tissue for comprehensive genomic profiling (CGP)).
| Patient Demographics and Baseline Characteristics | |
|---|---|
|
Gender: Men (%); Women (%) |
133 (59%); 94 (41%) |
|
Age: Median age (range) |
59 years (17–88) |
|
Ethnicity: Caucasian (%) |
163 (71.8%) |
| Asian (%) | 18 (8%) |
| Hispanic (%) | 18 (8%) |
| African American (%) | 8 (3.5%) |
| Other (%) | 20 (8.8%) |
| Histologies: | |
| Myeloid Disorders | N = 124 (54.6%) |
| Myelodysplastic syndrome (MDS) | 52 (22.9%) |
| Acute myeloid leukemia (AML) | 25 (11%) |
| Myeloproliferative neoplasia (MPN) | 21 (9.2%) |
| Multiple Myeloma (MM) | 17 (7.5%) |
| Chronic myeloid leukemia (CML) | 4 (1.8%) |
| Other myeloid disorders | 5 (2.2%) |
| Lymphoid disorders | N = 103 (45.4%) |
| Chronic lymphocytic leukemia (CLL) | 39 (17.2%) |
| Acute lymphocytic leukemia (ALL) | 20 (8.8%) |
| Diffuse large B-cell lymphoma (DLBCL) | 18 (7.9%) |
| Follicular lymphoma (FL) | 6 (2.6%) |
| Marginal zone lymphoma (MZL) | 4 (1.8%) |
| Anaplastic large cell lymphoma (ALCL) | 2 (0.9%) |
| Castleman disease | 2 (0.9%) |
| Other lymphoid disorders | 12 (5.3%) |
| Summary of alterations | |
| Number of patients with alterations | 197 (87%) |
| Number of patients with potentially actionable alterations | 170 (75%) |
| Median number of alterations/patient (range) | 3 (0–14) |
| Median number of potentially actionable alterations/patient (range) | 1 (0–7) |
| Total alterations | 698 |
| Number of distinct alterations | 546 |
| Number of distinct potentially actionable alterations | 256 |